J
Joel C Scherer
Researcher at Eli Lilly and Company
Publications - 16
Citations - 1854
Joel C Scherer is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Abciximab & TIMI. The author has an hindex of 10, co-authored 16 publications receiving 1771 citations.
Papers
More filters
Journal ArticleDOI
Abciximab Facilitates the Rate and Extent of Thrombolysis Results of the Thrombolysis In Myocardial Infarction (TIMI) 14 Trial
Elliott M. Antman,Robert P. Giugliano,C. Michael Gibson,Carolyn H. McCabe,P Coussement,Neal S. Kleiman,Alec Vahanian,A.A.Jennifer Adgey,Ian B. A. Menown,Hans J. Rupprecht,R. Van der Wieken,John Ducas,Joel C Scherer,Keaven M. Anderson,Frans Van de Werf,Eugene Braunwald +15 more
TL;DR: Abciximab facilitates the rate and extent of thrombolysis, producing early, marked increases in TIMI 3 flow when combined with half the usual dose of alteplase, and substantial reductions in heparin dosing may reduce the risk of bleeding even further.
Journal ArticleDOI
Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study
David W. Dodick,Peter J. Goadsby,Peter J. Goadsby,Egilius L.H. Spierings,Egilius L.H. Spierings,Egilius L.H. Spierings,Joel C Scherer,Steven Sweeney,David S Grayzel +8 more
TL;DR: Preliminary evidence is provided that LY2951742 might be beneficial in migraine prevention and support for the role of calcitonin gene-related peptide in the pathogenesis of migraine is provided.
Journal ArticleDOI
Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction: Observations from the TIMI 14 trial
James A. de Lemos,Elliott M. Antman,C. Michael Gibson,Carolyn H. McCabe,Robert P. Giugliano,Sabina A. Murphy,Stephanie Coulter,Keaven M. Anderson,Joel C Scherer,Martin J. Frey,R. Van der Wieken,Frans Van de Werf,Eugene Braunwald +12 more
TL;DR: Combination therapy with abciximab and reduced-dose tPA improves myocardial (microvascular) reperfusion, as reflected in greater ST-segment resolution, in addition to epicardial flow, which may translate into improved clinical outcomes by enhancing myocardIAL salvage.
Journal ArticleDOI
Double-Blind, Randomized Study Evaluating the Glycemic and Anti-inflammatory Effects of Subcutaneous LY2189102, a Neutralizing IL-1β Antibody, in Patients With Type 2 Diabetes
Joanne Sloan-Lancaster,Eyas Abu-Raddad,John Polzer,Jeffrey W. Miller,Joel C Scherer,Andrea De Gaetano,Jolene K. Berg,William H. Landschulz +7 more
TL;DR: In this paper, the authors evaluated the efficacy, safety, and tolerability of LY2189102, a neutralizing IL-1β antibody, in type 2 diabetes mellitus (T2DM) patients.
Journal ArticleDOI
Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14
Elliott M. Antman,C M Gibson,J.A. de Lemos,Robert P. Giugliano,Carolyn H. McCabe,P Coussement,Ian Menown,Christoph A. Nienaber,T.C Rehders,Martin J. Frey,R. Van der Wieken,D Andresen,Joel C Scherer,Keaven M. Anderson,F. Van de Werf,Eugene Braunwald +15 more
TL;DR: Reduced doses of reteplase when administered in combination with abciximab were associated with higher TIMI 3 flow rates than reported previously for reduced doses ofreteplases without abcximab and were at least as high as for full dose retePlase alone.